Report Detail

Request for Sample of this report

Pharma & Healthcare Global Biologics Monoclonal Antibodies Drug Market 2026 by Company, Regions, Type and Application, Forecast to 2032

  • RnM4742330
    • |
  • 28 September, 2026
    • |
  • Global
    • |
  • 116 Pages
    • |
  • GIR
    • |
  • Pharma & Healthcare

According to our (Global Info Research) latest study, the global Biologics Monoclonal Antibodies Drug market size was valued at US$ 301000 million in 2025 and is forecast to a readjusted size of US$ 648400 million by 2032 with a CAGR of 11.7% during review period.
Monoclonal antibodies are immune system proteins that are created in the lab. Antibodies are produced naturally by your body and help the immune system recognize germs that cause disease, such as bacteria and viruses, and mark them for destruction. Like your body’s own antibodies, monoclonal antibodies recognize specific targets.
The monoclonal antibody medicine market is driven by the growing demand for targeted and personalized therapies and the significant advancements in biotechnology and antibody engineering. Monoclonal antibodies (mAbs) offer precise targeting of specific antigens, making them highly effective in treating various diseases, including cancer, autoimmune disorders, and infectious diseases. Their ability to modulate the immune response and their potential for fewer side effects compared to traditional treatments have fueled their popularity among healthcare providers and patients. Moreover, the development of novel mAbs and the expansion of approved indications for existing therapies further contribute to market growth. However, the market also faces challenges, including the high cost of mAb therapies, which can limit patient access and reimbursement. Additionally, the complex manufacturing process and regulatory requirements for mAb medicines can be obstacles for new market entrants. To succeed in this competitive market, manufacturers must focus on improving affordability, exploring biosimilar opportunities, and investing in research and development to develop innovative and differentiated monoclonal antibody medicines that address unmet medical needs.
This report is a detailed and comprehensive analysis for global Biologics Monoclonal Antibodies Drug market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Biologics Monoclonal Antibodies Drug market size and forecasts, in consumption value ($ Million), 2021-2032
Global Biologics Monoclonal Antibodies Drug market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Biologics Monoclonal Antibodies Drug market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Biologics Monoclonal Antibodies Drug market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Biologics Monoclonal Antibodies Drug
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Biologics Monoclonal Antibodies Drug market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Amgen, AbbVie, Sanofi, Johnson & Johnson, Pfizer, Eli Lilly, Novartis, Merck, Biogen, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Biologics Monoclonal Antibodies Drug market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Infliximab
Rituximab
Trastuzumab
Adalimumab
Other
Market segment by Application
Cancer
Autoimmune Disease
Other
Market segment by players, this report covers
Roche
Amgen
AbbVie
Sanofi
Johnson & Johnson
Pfizer
Eli Lilly
Novartis
Merck
Biogen
Sobi
Innovent Biologics
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Biologics Monoclonal Antibodies Drug product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Biologics Monoclonal Antibodies Drug, with revenue, gross margin, and global market share of Biologics Monoclonal Antibodies Drug from 2021 to 2026.
Chapter 3, the Biologics Monoclonal Antibodies Drug competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Biologics Monoclonal Antibodies Drug market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Biologics Monoclonal Antibodies Drug.
Chapter 13, to describe Biologics Monoclonal Antibodies Drug research findings and conclusion.


1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Biologics Monoclonal Antibodies Drug by Type
    • 1.3.1 Overview: Global Biologics Monoclonal Antibodies Drug Market Size by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Global Biologics Monoclonal Antibodies Drug Consumption Value Market Share by Type in 2025
    • 1.3.3 Infliximab
    • 1.3.4 Rituximab
    • 1.3.5 Trastuzumab
    • 1.3.6 Adalimumab
    • 1.3.7 Other
  • 1.4 Global Biologics Monoclonal Antibodies Drug Market by Application
    • 1.4.1 Overview: Global Biologics Monoclonal Antibodies Drug Market Size by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Cancer
    • 1.4.3 Autoimmune Disease
    • 1.4.4 Other
  • 1.5 Global Biologics Monoclonal Antibodies Drug Market Size & Forecast
  • 1.6 Global Biologics Monoclonal Antibodies Drug Market Size and Forecast by Region
    • 1.6.1 Global Biologics Monoclonal Antibodies Drug Market Size by Region: 2021 VS 2025 VS 2032
    • 1.6.2 Global Biologics Monoclonal Antibodies Drug Market Size by Region, (2021-2032)
    • 1.6.3 North America Biologics Monoclonal Antibodies Drug Market Size and Prospect (2021-2032)
    • 1.6.4 Europe Biologics Monoclonal Antibodies Drug Market Size and Prospect (2021-2032)
    • 1.6.5 Asia-Pacific Biologics Monoclonal Antibodies Drug Market Size and Prospect (2021-2032)
    • 1.6.6 South America Biologics Monoclonal Antibodies Drug Market Size and Prospect (2021-2032)
    • 1.6.7 Middle East & Africa Biologics Monoclonal Antibodies Drug Market Size and Prospect (2021-2032)

2 Company Profiles

  • 2.1 Roche
    • 2.1.1 Roche Details
    • 2.1.2 Roche Major Business
    • 2.1.3 Roche Biologics Monoclonal Antibodies Drug Product and Solutions
    • 2.1.4 Roche Biologics Monoclonal Antibodies Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Roche Recent Developments and Future Plans
  • 2.2 Amgen
    • 2.2.1 Amgen Details
    • 2.2.2 Amgen Major Business
    • 2.2.3 Amgen Biologics Monoclonal Antibodies Drug Product and Solutions
    • 2.2.4 Amgen Biologics Monoclonal Antibodies Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Amgen Recent Developments and Future Plans
  • 2.3 AbbVie
    • 2.3.1 AbbVie Details
    • 2.3.2 AbbVie Major Business
    • 2.3.3 AbbVie Biologics Monoclonal Antibodies Drug Product and Solutions
    • 2.3.4 AbbVie Biologics Monoclonal Antibodies Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 AbbVie Recent Developments and Future Plans
  • 2.4 Sanofi
    • 2.4.1 Sanofi Details
    • 2.4.2 Sanofi Major Business
    • 2.4.3 Sanofi Biologics Monoclonal Antibodies Drug Product and Solutions
    • 2.4.4 Sanofi Biologics Monoclonal Antibodies Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Sanofi Recent Developments and Future Plans
  • 2.5 Johnson & Johnson
    • 2.5.1 Johnson & Johnson Details
    • 2.5.2 Johnson & Johnson Major Business
    • 2.5.3 Johnson & Johnson Biologics Monoclonal Antibodies Drug Product and Solutions
    • 2.5.4 Johnson & Johnson Biologics Monoclonal Antibodies Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Johnson & Johnson Recent Developments and Future Plans
  • 2.6 Pfizer
    • 2.6.1 Pfizer Details
    • 2.6.2 Pfizer Major Business
    • 2.6.3 Pfizer Biologics Monoclonal Antibodies Drug Product and Solutions
    • 2.6.4 Pfizer Biologics Monoclonal Antibodies Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Pfizer Recent Developments and Future Plans
  • 2.7 Eli Lilly
    • 2.7.1 Eli Lilly Details
    • 2.7.2 Eli Lilly Major Business
    • 2.7.3 Eli Lilly Biologics Monoclonal Antibodies Drug Product and Solutions
    • 2.7.4 Eli Lilly Biologics Monoclonal Antibodies Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Eli Lilly Recent Developments and Future Plans
  • 2.8 Novartis
    • 2.8.1 Novartis Details
    • 2.8.2 Novartis Major Business
    • 2.8.3 Novartis Biologics Monoclonal Antibodies Drug Product and Solutions
    • 2.8.4 Novartis Biologics Monoclonal Antibodies Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Novartis Recent Developments and Future Plans
  • 2.9 Merck
    • 2.9.1 Merck Details
    • 2.9.2 Merck Major Business
    • 2.9.3 Merck Biologics Monoclonal Antibodies Drug Product and Solutions
    • 2.9.4 Merck Biologics Monoclonal Antibodies Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Merck Recent Developments and Future Plans
  • 2.10 Biogen
    • 2.10.1 Biogen Details
    • 2.10.2 Biogen Major Business
    • 2.10.3 Biogen Biologics Monoclonal Antibodies Drug Product and Solutions
    • 2.10.4 Biogen Biologics Monoclonal Antibodies Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Biogen Recent Developments and Future Plans
  • 2.11 Sobi
    • 2.11.1 Sobi Details
    • 2.11.2 Sobi Major Business
    • 2.11.3 Sobi Biologics Monoclonal Antibodies Drug Product and Solutions
    • 2.11.4 Sobi Biologics Monoclonal Antibodies Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Sobi Recent Developments and Future Plans
  • 2.12 Innovent Biologics
    • 2.12.1 Innovent Biologics Details
    • 2.12.2 Innovent Biologics Major Business
    • 2.12.3 Innovent Biologics Biologics Monoclonal Antibodies Drug Product and Solutions
    • 2.12.4 Innovent Biologics Biologics Monoclonal Antibodies Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 Innovent Biologics Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Biologics Monoclonal Antibodies Drug Revenue and Share by Players (2021-2026)
  • 3.2 Market Share Analysis (2025)
    • 3.2.1 Market Share of Biologics Monoclonal Antibodies Drug by Company Revenue
    • 3.2.2 Top 3 Biologics Monoclonal Antibodies Drug Players Market Share in 2025
    • 3.2.3 Top 6 Biologics Monoclonal Antibodies Drug Players Market Share in 2025
  • 3.3 Biologics Monoclonal Antibodies Drug Market: Overall Company Footprint Analysis
    • 3.3.1 Biologics Monoclonal Antibodies Drug Market: Region Footprint
    • 3.3.2 Biologics Monoclonal Antibodies Drug Market: Company Product Type Footprint
    • 3.3.3 Biologics Monoclonal Antibodies Drug Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Biologics Monoclonal Antibodies Drug Consumption Value and Market Share by Type (2021-2026)
  • 4.2 Global Biologics Monoclonal Antibodies Drug Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

  • 5.1 Global Biologics Monoclonal Antibodies Drug Consumption Value Market Share by Application (2021-2026)
  • 5.2 Global Biologics Monoclonal Antibodies Drug Market Forecast by Application (2027-2032)

6 North America

  • 6.1 North America Biologics Monoclonal Antibodies Drug Consumption Value by Type (2021-2032)
  • 6.2 North America Biologics Monoclonal Antibodies Drug Market Size by Application (2021-2032)
  • 6.3 North America Biologics Monoclonal Antibodies Drug Market Size by Country
    • 6.3.1 North America Biologics Monoclonal Antibodies Drug Consumption Value by Country (2021-2032)
    • 6.3.2 United States Biologics Monoclonal Antibodies Drug Market Size and Forecast (2021-2032)
    • 6.3.3 Canada Biologics Monoclonal Antibodies Drug Market Size and Forecast (2021-2032)
    • 6.3.4 Mexico Biologics Monoclonal Antibodies Drug Market Size and Forecast (2021-2032)

7 Europe

  • 7.1 Europe Biologics Monoclonal Antibodies Drug Consumption Value by Type (2021-2032)
  • 7.2 Europe Biologics Monoclonal Antibodies Drug Consumption Value by Application (2021-2032)
  • 7.3 Europe Biologics Monoclonal Antibodies Drug Market Size by Country
    • 7.3.1 Europe Biologics Monoclonal Antibodies Drug Consumption Value by Country (2021-2032)
    • 7.3.2 Germany Biologics Monoclonal Antibodies Drug Market Size and Forecast (2021-2032)
    • 7.3.3 France Biologics Monoclonal Antibodies Drug Market Size and Forecast (2021-2032)
    • 7.3.4 United Kingdom Biologics Monoclonal Antibodies Drug Market Size and Forecast (2021-2032)
    • 7.3.5 Russia Biologics Monoclonal Antibodies Drug Market Size and Forecast (2021-2032)
    • 7.3.6 Italy Biologics Monoclonal Antibodies Drug Market Size and Forecast (2021-2032)

8 Asia-Pacific

  • 8.1 Asia-Pacific Biologics Monoclonal Antibodies Drug Consumption Value by Type (2021-2032)
  • 8.2 Asia-Pacific Biologics Monoclonal Antibodies Drug Consumption Value by Application (2021-2032)
  • 8.3 Asia-Pacific Biologics Monoclonal Antibodies Drug Market Size by Region
    • 8.3.1 Asia-Pacific Biologics Monoclonal Antibodies Drug Consumption Value by Region (2021-2032)
    • 8.3.2 China Biologics Monoclonal Antibodies Drug Market Size and Forecast (2021-2032)
    • 8.3.3 Japan Biologics Monoclonal Antibodies Drug Market Size and Forecast (2021-2032)
    • 8.3.4 South Korea Biologics Monoclonal Antibodies Drug Market Size and Forecast (2021-2032)
    • 8.3.5 India Biologics Monoclonal Antibodies Drug Market Size and Forecast (2021-2032)
    • 8.3.6 Southeast Asia Biologics Monoclonal Antibodies Drug Market Size and Forecast (2021-2032)
    • 8.3.7 Australia Biologics Monoclonal Antibodies Drug Market Size and Forecast (2021-2032)

9 South America

  • 9.1 South America Biologics Monoclonal Antibodies Drug Consumption Value by Type (2021-2032)
  • 9.2 South America Biologics Monoclonal Antibodies Drug Consumption Value by Application (2021-2032)
  • 9.3 South America Biologics Monoclonal Antibodies Drug Market Size by Country
    • 9.3.1 South America Biologics Monoclonal Antibodies Drug Consumption Value by Country (2021-2032)
    • 9.3.2 Brazil Biologics Monoclonal Antibodies Drug Market Size and Forecast (2021-2032)
    • 9.3.3 Argentina Biologics Monoclonal Antibodies Drug Market Size and Forecast (2021-2032)

10 Middle East & Africa

  • 10.1 Middle East & Africa Biologics Monoclonal Antibodies Drug Consumption Value by Type (2021-2032)
  • 10.2 Middle East & Africa Biologics Monoclonal Antibodies Drug Consumption Value by Application (2021-2032)
  • 10.3 Middle East & Africa Biologics Monoclonal Antibodies Drug Market Size by Country
    • 10.3.1 Middle East & Africa Biologics Monoclonal Antibodies Drug Consumption Value by Country (2021-2032)
    • 10.3.2 Turkey Biologics Monoclonal Antibodies Drug Market Size and Forecast (2021-2032)
    • 10.3.3 Saudi Arabia Biologics Monoclonal Antibodies Drug Market Size and Forecast (2021-2032)
    • 10.3.4 UAE Biologics Monoclonal Antibodies Drug Market Size and Forecast (2021-2032)

11 Market Dynamics

  • 11.1 Biologics Monoclonal Antibodies Drug Market Drivers
  • 11.2 Biologics Monoclonal Antibodies Drug Market Restraints
  • 11.3 Biologics Monoclonal Antibodies Drug Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Biologics Monoclonal Antibodies Drug Industry Chain
  • 12.2 Biologics Monoclonal Antibodies Drug Upstream Analysis
  • 12.3 Biologics Monoclonal Antibodies Drug Midstream Analysis
  • 12.4 Biologics Monoclonal Antibodies Drug Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    Summary:
    Get latest Market Research Reports on Biologics Monoclonal Antibodies Drug. Industry analysis & Market Report on Biologics Monoclonal Antibodies Drug is a syndicated market report, published as Global Biologics Monoclonal Antibodies Drug Market 2026 by Company, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Biologics Monoclonal Antibodies Drug market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    		$3,480.00
    		$5,220.00
    		$6,960.00
    		2,690.04
    		4,035.06
    		5,380.08
    		3,239.88
    		4,859.82
    		6,479.76
    		531,361.20
    		797,041.80
    		1,062,722.40
    		293,712.00
    		440,568.00
    		587,424.00
    Credit card Logo
    Sample Question Discount Download PDF

    Related Reports

    Reason to Buy

    • Trusted By Leaders

      Top executives from leading companies purchase research reports from us. 

    • Shop With Confidence

      We assist you with all the pre-sales enquiries related to any report so that you can buy with confidence.

    • Customer Centric

      Need assistance related to your research requirements? We are just a phone call or an email away.

    • Personalized Solutions

      Our experienced research specialists are here to help you locate the right reports for your need.

    • Secure Checkout

      Shop without being worried about safety & security of your transactions.
      •

    Request for Sample of this report

    Reports and Markets

    mcafree

    Contact Us

    +1-352-353-0818 (US)

    info@reportsandmarkets.com

    Support

    EMAIL US

    Newsletter

    KEEP UP TO DATE ON ALL THE LATEST REPORTS


    maxmind_logo